Enzyme Inhibition
Enzyme inhibition is the decrease of an enzyme's catalytic activity by a molecule that binds to the enzyme or its complexes. It is one of the central mechanisms by which cells regulate metabolism and by which a large fraction of drugs and toxins act. This area orients the reader to how inhibitors are classified, how their effect is measured kinetically, and why inhibition matters in physiology and therapeutics.
Definition
Enzyme inhibition is the reduction of the rate of an enzyme-catalysed reaction caused by an inhibitor that binds to the free enzyme, the enzyme-substrate complex, or both, thereby lowering the apparent catalytic efficiency.
Scope
The area covers reversible inhibition (competitive, noncompetitive, uncompetitive, and mixed types), irreversible and mechanism-based inactivation, the physiological control of pathways by feedback inhibition, and the broader processes of enzyme inactivation and degradation. It treats these as biochemical and methodological topics, not as prescriptive clinical advice.
Sub-topics
Core questions
- Does an inhibitor bind reversibly or form a covalent, essentially permanent bond?
- Which kinetic constants (Km, Vmax) does the inhibitor alter, and what does that reveal about its binding site?
- How is inhibitory potency quantified (Ki, IC50, kinact/Ki) and compared across compounds?
- How do cells use inhibition, especially feedback inhibition, to regulate metabolic flux?
Key concepts
- Reversible vs irreversible inhibition
- Competitive, noncompetitive, uncompetitive, and mixed inhibition
- Inhibition constant (Ki) and IC50
- Allosteric and active-site inhibition
- Feedback (end-product) inhibition
- Mechanism-based (suicide) inactivation
- Enzyme turnover and degradation
Key theories
- Steady-state kinetic model of inhibition
- Reversible inhibitors are classified by how they shift the Michaelis-Menten parameters: competitive inhibitors raise the apparent Km without changing Vmax, noncompetitive inhibitors lower Vmax without changing Km, and uncompetitive and mixed types alter both. Graphical and replot methods estimate the inhibition constant Ki.
- Allosteric (MWC) model of regulation
- The Monod-Wyman-Changeux model explains how regulatory enzymes shift between tense and relaxed conformations, providing a structural basis for feedback inhibition and cooperative inhibition at sites distinct from the active site.
Mechanisms
Reversible inhibitors bind through non-covalent interactions and can dissociate; their kinetic signature depends on whether they bind the free enzyme (competitive), the enzyme-substrate complex (uncompetitive), or both (noncompetitive and mixed), as captured by the steady-state kinetic framework (Goldstein, 1944; Cornish-Bowden, 1974). Irreversible inhibitors form stable, often covalent, bonds and progressively inactivate the enzyme. Regulatory enzymes additionally respond to inhibitors at allosteric sites, and the Monod-Wyman-Changeux model frames this as a shift in conformational equilibrium (Monod, 1965). Cells exploit such regulation through feedback inhibition, in which the end product of a pathway inhibits an early committed step (Umbarger, 1956).
Clinical relevance
Many therapeutic agents and toxins act as enzyme inhibitors, and a working knowledge of inhibition types underlies how their potency, selectivity, and duration of action are described and compared (Copeland, 2013). This entry explains the biochemical basis of such effects for reference and education; it does not provide dosing or individualized treatment guidance.
History
The quantitative study of inhibition grew out of early twentieth-century enzyme kinetics, with the steady-state treatment of inhibitor-substrate competition formalised by the 1940s (Goldstein, 1944). Mid-century work on biosynthetic pathways revealed feedback inhibition as a regulatory principle (Umbarger, 1956), and the 1965 allosteric model gave a structural account of regulation away from the active site (Monod, 1965). Later graphical and computational methods refined the estimation of inhibition constants (Cornish-Bowden, 1974).
Key figures
- Jacques Monod
- Jean-Pierre Changeux
- H. Edwin Umbarger
- Athel Cornish-Bowden
- Avram Goldstein
Related topics
Seminal works
- goldstein-1944
- monod-1965
- umbarger-1956
- cornish-bowden-1974
Frequently asked questions
- What is the difference between reversible and irreversible inhibition?
- A reversible inhibitor binds non-covalently and can dissociate, so activity returns when it is removed; an irreversible inhibitor forms a stable, usually covalent, bond and permanently inactivates the enzyme until new enzyme is made.
- How is the strength of an inhibitor measured?
- Reversible inhibitors are characterised by an inhibition constant (Ki) or an IC50, the concentration giving 50 percent inhibition; irreversible inhibitors are characterised by the rate of inactivation relative to binding (kinact/Ki).